Business Description
Matinas BioPharma Holdings is a New Jersey-based clinical-stage drug development company founded in 2013, focused on making medicines easier and safer for patients to take through its proprietary lipid nanocrystal delivery system. This technology wraps drug compounds in tiny fat-based particles, enabling treatments that would otherwise require injection ? including gene therapies, vaccines, and proteins ? to be taken by mouth instead. The company's most advanced drug candidate, MAT2203, is an oral treatment for serious fungal infections currently entering Phase 3 trials, and Matinas has also formed research partnerships with organizations such as BioNTech and Genentech to explore broader applications of its platform.
